Last reviewed · How we verify
Losartan + hydrochlorothiazide in fixed dose
Losartan blocks angiotensin II receptors to reduce vasoconstriction, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure.
Losartan blocks angiotensin II receptors to reduce vasoconstriction, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure. Used for Hypertension (essential hypertension), Reduction of cardiovascular morbidity and mortality in hypertensive patients at high risk.
At a glance
| Generic name | Losartan + hydrochlorothiazide in fixed dose |
|---|---|
| Also known as | LOS/HYDROCHLO |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Angiotensin II receptor antagonist + thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the adrenal gland, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing urinary sodium and water loss. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension (essential hypertension)
- Reduction of cardiovascular morbidity and mortality in hypertensive patients at high risk
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia (losartan component)
- Hypokalemia (hydrochlorothiazide component)
- Hyperuricemia
- Cough
- Headache
- Hypotension
Key clinical trials
- Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension (PHASE3)
- Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED) (PHASE4)
- The SCCS Polypill Pilot Trial (PHASE2)
- Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions (PHASE1)
- Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions. (PHASE1)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
- Kanagawa Combination Anti-hypertensive Therapy (K-CAT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: